Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
201
resultados
Última actualización
28/02/2026 [06:56:00]
Resultados 75 a 100 de 201
Resumen de: AU2024267555A1
The invention relates to the production, modification, and use of extracellular vesicles (EVs), particularly for the delivery of payloads of nucleic acids. The EVs can contain retroviral capsids and can be coated with polymers. The EVs can be treated with a protease to remove proteins on the outer surface of the EV to create shaved EVs. The shaved EVs can be coated with a polymer and used for the delivery of payloads of nucleic acids to cells.
Resumen de: WO2025052296A1
The present invention belongs to the field of biomedicine and drug delivery as well as pest and vector controls. The invention relates to a novel ionizable cationic lipid family incorporating silicon, which belongs to the trademark LipexSil® second generation lipids, wherein the tail is connected to the headgroup with biodegradable silyl acetal linker. Lipids containing silyl acetal linker(s) are state-of-the-art and are effective as ionizable cationic lipids in the formulation of empty or loaded lipid nanoparticles (LNPs). The novel linkers according to the invention are designed by means of proprietary borane catalysts WO2022129966. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, dsRNA, pDNA, micro RNA, circular DNA, small biologically active molecules) into the cells.
Resumen de: CN121550427A
本发明公开了一种外泌体包裹的球形ICG光免疫激活剂CND‑ICG@Exo及其制备方法和应用，属于纳米生物医药技术领域。该光免疫激活剂由碳点材料CND与吲哚菁绿ICG通过酯化反应形成CND‑ICG复合物，再经超声法包裹肿瘤细胞外泌体TDEs制备而成。本发明通过CND与ICG的共价偶联，解决了游离ICG光稳定性差、水溶性低、体内消除快的缺陷；结合TDEs的肿瘤靶向性与免疫激活能力，使光免疫激活剂在三阴性乳腺癌TNBC肿瘤部位高效富集，激光照射下可实现光热杀瘤与免疫激活协同作用，同时具备近红外成像功能。该激活剂对肿瘤细胞杀伤率高，且生物安全性良好，为TNBC的精准诊疗一体化提供了新的技术方案。
Resumen de: WO2024235481A1
The invention relates to lipid nanoparticles containing selected quantities of a) at least one cationic lipid, b) at least one phospholipid, and c) at least one selected stealth lipid, with the proviso that all the lipids contained in the lipid nanoparticle have an HLB value of greater than or equal to 3. These nanoparticles can be charged with active substances containing anionic groups, preferably with nucleic acids, and are suitable as highly efficient vehicles for transferring nucleic acids into cells.
Resumen de: AU2024304918A1
Poly(oxazoline) conjugates with pendant cationic groups (cationic POZ) and lipid nanoparticles (LNPs) including cationic POZ used to facilitate delivery of an encapsulated payload. LNPs and polyplexes including cationic POZ and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing an ionizable lipid.
Resumen de: WO2024256457A1
The present invention provides, in part, tricene and citric acid-based cationic lipids with aromatic head groups of Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: CN121550178A
本发明涉及生物制药技术领域，具体涉及一种吉西他滨纳米颗粒、抗肿瘤联合用药物及应用，所述吉西他滨纳米颗粒由吉西他滨内核和包覆其外的细胞膜组成；所述细胞膜来源于经基因工程改造后过表达PD‑1的CT26‑PD‑1细胞；所述吉西他滨纳米颗粒粒径大小为150nm~200nm。本发明通过过表达PD‑1的肿瘤细胞膜包覆吉西他滨，借助PD‑1和PD‑L1的相互作用增强了吉西他滨在肿瘤中富集的能力，改善了吉西他滨的生物毒性和较短的血液半衰期；并通过联合CD73抑制剂AB680实现对结直肠癌的精准靶向递送和免疫微环境调控，为肿瘤治疗提供了一种高效、低毒的创新方案。
Resumen de: AU2024275548A1
The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Resumen de: CN121550423A
本发明公开了一种用于梅毒光驱动治疗的多功能仿生纳米粒子及其制备方法和应用。所述多功能仿生纳米粒子为外膜包覆核心的结构，所述外膜为被梅毒螺旋体预先激活的巨噬细胞的细胞膜，所述核心为具有AIE型光敏剂复合材料。本发明提供的多功能仿生纳米粒子可实现梅毒硬下疳和硬下疳内病原体的分级靶向，表现出对皮疹的精确跟踪和近红外区I区荧光成像；在808nm激光照射下，多功能仿生纳米粒子产生高效的光热和光动力效应，梅毒螺旋体可以被光裂解消除，从而实现梅毒的无创光疗。该多功能仿生纳米粒子不仅可以作为仿生纳米药物用于梅毒的靶向治疗，降低药物的毒副作用，还可以同时实现高分辨率成像，达到多模态综合诊疗的目的。
Resumen de: WO2025021083A1
Provided herein is a lipid nanoparticle (LNP) composition for the localized treatment of skin diseases and a method of treating skin diseases with the LNP composition.
Resumen de: CN121550391A
本发明公开了一种基于中药活性成分的肾癌靶向纳米片剂及其制备方法，其特征在于：包括补益脾肾组分、滋阴潜阳组分、活血化瘀组分、清热解毒组分和温阳化气组分，通过对原料预处理，收集各药材的提取物；活性成分纳米化，获得粒径均匀的纳米粒混悬液；靶向配体修饰，获得功能化纳米粒混悬液；以微晶纤维素为骨架材料，羟丙基甲基纤维素为粘合剂，采用直接压片法制备片芯；采用高效包衣锅进行三层包衣；质量检测与包装，确保产品稳定性和用药安全。本发明兼具传统中药多靶点作用和现代纳米技术靶向递送优势的肾癌治疗纳米片剂，通过特殊辅料与引经药构建靶向通路，提高药物在肾癌组织的富集，增强治疗效果。
Resumen de: CN121550253A
本发明涉及一种具有超氧化物歧化酶活性的铜离子/没食子酸纳米酶及其制备方法与应用。该纳米酶由铜离子、没食子酸与氢氧化钠在去离子水中反应形成，反应在约30℃的水浴条件下进行1至3小时，所得纳米酶经离心富集获得。所述铜离子、没食子酸与氢氧化钠的摩尔投料比为1:1:0.5至1:1:2，铜源可选用三水合硝酸铜或二水合氯化铜。本发明纳米酶具有良好的分散性和稳定性，表现出优异的超氧阴离子清除能力，模拟天然超氧化物歧化酶活性，适用于制备治疗氧化应激相关疾病的药物，特别是在炎症性疾病、心脑血管疾病及神经退行性疾病等领域具有广阔的应用前景。
Resumen de: CN121549483A
本发明涉及保健品领域，具体涉及一种纳米中药灵芝保健品固体饮料及其制备方法，该固体饮料主要由纳米灵芝提取物、低聚果糖、木糖醇、抗性糊精、柠檬酸、苹果酸、天然香料及甜味剂组成。其制备方法包括灵芝预处理、纳米处理、提取、浓缩、调配、干燥和包装步骤。本发明通过纳米研磨技术将灵芝粉碎成纳米级粉末，增加了灵芝与溶剂的接触面积，结合超声辅助提取、微波辅助提取或酶解辅助提取等技术，可显著提高灵芝有效成分的提取率。同时，纳米级灵芝粉末和能量植入使灵芝分子的活性和能量状态发生改变，更易于被人体吸收，提高了生物利用度。
Resumen de: CN121550185A
本发明公开了一种双蛋白微胶囊及其应用，该微胶囊由乳铁蛋白分别与α‑乳白蛋白、β‑乳球蛋白或酪蛋白形成的双蛋白复合物，结合海藻酸钠经内源乳化法包封益生菌制得。其核心优势在于双蛋白复合物通过空间屏障作用增强胃酸耐受性，益生元效应协同海藻酸钠的控释特性，大幅提升益生菌肠道活性保留与靶向释放效率；“物理保护‑营养协同”双重机制赋予微胶囊28天优异贮藏稳定性。本发明将双蛋白特异性相互作用与多糖包封技术结合，提供了可复制的优化参数与理论依据，有效解决益生菌递送中“活性‑释放‑贮藏”协同难题，为合生元微胶囊精准设计提供参考。
Resumen de: CN121550183A
本申请涉及一种铑纳米酶复合物及其在制备预防、缓解和/或治疗药物性肝损伤的药物中的应用，其包括细胞外囊泡模拟物以及位于所述细胞外囊泡模拟物内的铑纳米酶。铑纳米酶表面包覆有细胞外囊泡模拟物，细胞外囊泡模拟物具有良好的生物相容性、低免疫原性，并能促进组织修复与再生，细胞外囊泡模拟物会被非特异性地清除，进而靶向富集在肝脏，这使得铑纳米酶一起被富集在肝脏，而铑纳米酶具有优异的超氧化物歧化酶SOD和过氧化氢酶CAT模拟活性，能高效清除多种活性氧物种，可以抑制APAP引发的炎症反应，从而对药物性肝损伤具有靶向治疗效果。
Resumen de: CN121554604A
本发明名称为一种结核分枝杆菌mRNA疫苗及其构建方法与应用，属于生物医药技术领域。所要解决的技术问题为提供一种剂量低、安全性高、免疫记忆持久的新型结核分枝杆菌mRNA疫苗。技术方案要点为将编码Hsp65和Mpt83抗原串联表达，结合tPA信号肽（SEQ ID NO:1）、MITD序列（SEQ ID NO:5）及柔性Linker（SEQ ID NO:6‑7）构建mRNA分子，再通过密码子优化（mRNA二级结构、GC含量）和脂质纳米颗粒（LNP）包封工艺，最终获得一种新型结核分枝杆菌mRNA疫苗。
Resumen de: CN121550179A
本发明涉及药物制剂技术领域，提供一种透明质酸钠‑地塞米松纳米颗粒、其制备方法及应用。该方法中，将地塞米松溶解于乙醇得到地塞米松‑乙醇溶液，将透明质酸钠溶解于水性溶剂得到透明质酸钠水溶液，并对透明质酸钠水溶液预热；随后采用微流控合成装置，将地塞米松‑乙醇溶液作为脂相、预热后的透明质酸钠水溶液作为水相，以设定的总流速及脂相与水相流速比同步注入微流控混合通道，在通道内原位形成透明质酸钠‑地塞米松纳米颗粒分散液，并进行固化处理，必要时进一步分散于磷酸盐缓冲液中。所得纳米颗粒具有粒径小、分散性好、稳定性高和便于表面修饰等优点，可用于制备用于预防或治疗炎症性疾病的药物。
Resumen de: CN121550176A
本发明属于生物医药技术领域，更具体地，涉及一种ROS响应型脂质体复合材料及其制备方法与应用，所述ROS响应型脂质体复合材料是将紫草素和瑞舒伐他汀共同负载到含有ROS敏感性连接物DSPE‑TK‑PEG2000修饰的脂质体上，进一步将仿生膜包裹在外层，即得所述ROS响应型脂质体复合材料。本发明利用ROS响应的设计特点，实现药物在病变部位的特异性聚集和响应型释放，并有效延长药物的血液循环半衰期，结合紫草素和瑞舒伐他汀两种不同机理的抗动脉粥样硬化效应，达到有效治疗同型半胱氨酸诱导的动脉粥样硬化的效果。
Resumen de: CN121550182A
本发明属于微生物技术领域，提供了一种包裹有金属‑多酚二次配位纳米涂层的微生物及其制备方法与应用。本发明通过聚乙烯吡咯烷酮、金属离子与多酚自组装形成金属‑多酚纳米颗粒，随后利用纳米颗粒与金属离子的二次配位作用在微生物表面快速沉积连续纳米涂层，所得涂层厚度约为100 nm。本发明的涂层构建方法适用于不同类型微生物，且涂层对微生物的正常生长无显著影响，具有良好的生物相容性。同时该纳米涂层能够选择性促进革兰氏阴性益生菌EcN的生物膜形成。在模拟肠道黏液体系中，该促进效果仍能保持。本发明可用于提高益生菌黏附及定植能力，并适用于益生菌制剂、微生态调控体系的构建。
Resumen de: CN121550184A
本发明属于生物医药技术领域，涉及一种斑蝥素智能药物递送系统。本发明通过一种具有精确pH响应功能的聚合物杂化载体来递送斑蝥素，实现了斑蝥素的高效递送并显著改善了斑蝥素的组织分布与释药性能，特别是该体系可以具有良好的溶酶体逃逸功能，显著提升了斑蝥素抗乳腺癌的疗效与安全性。
Resumen de: MX2025013219A
The present invention is directed to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, the nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infections in a mammal. The invention is further directed to nucleic acid-based vaccine compositions and a kit of parts comprising the vaccine compositions, as well as methods of treatment and medical uses relating to the nucleic acids, vaccine compositions, and kit of parts.
Resumen de: GB2643476A
The disclosure provides, in various embodiments, fusion proteins comprising a DNA-binding domain, a DNMT3 A-binding domain, and a H3K4me0; and polynucleotides and vectors encoding one or more of the fusion proteins. The disclosure also provides, in various embodiments, gene-delivery systems, cells, compositions (e.g., pharmaceutical compositions) and kits comprising one or more of the fusion proteins polynucleotides, or vectors; methods of epigenetically modifying a genomic locus in a cell; and methods of treating a subject (e.g., a human) in need thereof.
Resumen de: NZ824476A
The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.
Resumen de: CN121002050A
The present disclosure relates, inter alia, to polynucleotides encoding modified interleukin 2 (IL-2) polypeptides and fusion proteins comprising such modified IL-2 polypeptides, vectors comprising such polynucleotides, pharmaceutical compositions comprising such polynucleotides and vectors, pharmaceutical compositions comprising such polynucleotides, and pharmaceutical compositions comprising such polynucleotides. And methods of treating diseases and conditions by administering such polynucleotides, vectors, and/or pharmaceutical compositions.
Nº publicación: JP2026028253A 19/02/2026
Solicitante:
エソレイト・リミテッド
Resumen de: US2024269085A1
The present invention provides stable, non-degradable edible, inhalable, soluble and drinkable compositions comprising highly bioavailable pharmaceutical grade ultrafine active pharmaceutical ingredients having 99% purity and 200% increased bioavailability and methods for their production.
BOPI
Sede Electrónica
